Chi­nese biotech bags $50M+ for I/O, au­toim­mune work, start­ing with ALK5 in­hibitor

For the last decade or so, many of the more eye-catch­ing Chi­nese biotech star­tups share two defin­ing at­trib­ut­es: sea­soned ex­ecs trained at multi­na­tion­al bio­phar­ma com­pa­nies and a mis­sion to bridge the gap be­tween West­ern med­ical break­throughs and Chi­nese pa­tients.

In re­cent years, a new gen­er­a­tion has emerged build­ing on that, with lead­ers who have now test­ed the wa­ters at the pi­o­neer­ing com­pa­nies and ex­pressed am­bi­tions to not just be first in Chi­na, but to beat glob­al ri­vals to a his­toric ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER